Table 1.
Demographics and clinical characteristics of the sub-set of women who acquire HIV infections during the CAPRISA 004 trials (n = 48).
| Characteristics | All (n = 48) | Tenofovir (n = 24) | Placebo (n = 24) | p value |
|---|---|---|---|---|
| Rural % (n) | 58.3% (28) | 58.3% (14) | 58.3% (14) | ns |
| Median age in years (IQR) | 23 (22–25) | 24 (22–28) | 22 (22–23) | ns |
| Median days PI at enrolment (IQR) | 38 (24–65) | 35 (27–63) | 45 (23–65) | ns |
| Median CD4 count (cells/μl) (IQR) | 498 (434–655) | 468 (444–569) | 515 (433–685) | ns |
| Median viral load (copies/ml) (IQR) | 59,0505 | 80,600 | 54.800 | ns |
| (17,300–135,500) | (22,000–130,000) | (13,600–148,000) | ns | |
| Time to HIV infection from enrolment in months (IQR) | 9.2 (4.9–14.1) | 12.8 (6.6–16.6) | 7.4 (3.3–10.6) | 0.02 |
| Completed high school % (n) | 54.2% (26) | 41.7% (10) | 66.7% (16) | ns |
| Hormonal contraceptive usea % (n) | 97.9% (47) | 100% (24) | 95.8% (23) | ns |
| Marital Status % (n) | ||||
| Stable/married partner | 79.2% (38) | 87.5% (21) | 70.8 (17) | ns |
| Single | 18.7% (9) | 12.5% (3) | 25.0% (6) | ns |
| >2 partners | 2.1% (1) | 0.0% (0) | 4.2% (1) | ns |
| Numbers of reported sexual partners in the last 3 months % (n) | ||||
| 0 to 1 | 93.8% (45) | 95.8% (23) | 91.7% (22)b | ns |
| 2 to 5 | 6.2% (3) | 4.2% (1) | 8.3% (2) | ns |
| Reported condom used at last sex act % (n) | 68.8% (33) | 75.0% (18) | 62.5% (15) | ns |
IQR, interquartile range; PI, post-infection.
Significant values were defined as p < 0.05 and indicated in bold text.
a
Hormonal contraception use included the injectable norethisterone and depomedroxyprogesterone acetate, and oral contraception. One woman in the placebo arm of the study was using an intrauterine device.
b
Two non-rapid progressing women had missing sexual partner data (in previous 3 months) as they refused to answer the question.